A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
Trial details
- Registry ID
- NCT03834753
- Phase
- Phase 3
The FDA approved ranibizumab on 30 Jun 2006.
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)NCT03834753 | OTLK | Phase 3 | Completed | 2021-06-07Actual |
| A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)NCT06190093 | OTLK | Phase 3 | Completed | 2024-11-07Actual |
| A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)NCT03844074 | OTLK | Phase 3 | Completed | 2020-07-23Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2006-06-30Day | ranibizumab | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "BLA125156", "applicant_as_listed_by_fda": "GENENTECH", "brand_names": ["LUCENTIS"], "active_ingredients": ["RANIBIZUMAB"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20060630", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |